Literature DB >> 16533240

Coexisting subacute and systemic lupus erythematosus after terbinafine administration: successful treatment with mycophenolate mofetil.

Petra Cetkovská1, Karel Pizinger.   

Abstract

A 39-year-old female patient with systemic lupus erythematosus was treated with terbinafine for onychomycosis. After only 7 days of treatment with 250 mg terbinafine, a widespread severe erythematous eruption developed. The results of clinical, histological and immunofluorescent examinations confirmed the diagnosis of coexisting subacute and systemic lupus erythematosus. The patient was treated with drug withdrawal and administration of cyclosporine and methylprednisolone. One year later, mycophenolate mofetil was successfully used. Exacerbation or induction of lupus erythematosus is an extremely rare cutaneous side-effect of terbinafine. Patients with lupus erythematosus should be advised about the risk of some drugs that might exacerbate their disease.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16533240     DOI: 10.1111/j.1365-4632.2004.02472.x

Source DB:  PubMed          Journal:  Int J Dermatol        ISSN: 0011-9059            Impact factor:   2.736


  4 in total

1.  Rare Occurrence of Drug Induced Subacute Cutaneous Lupus Erythematosus with Leflunomide Therapy.

Authors:  Harpreet Singh; Gagandeep Sukhija; Vikram Tanwar; Sameer Arora; Jaikrit Bhutani
Journal:  J Clin Diagn Res       Date:  2016-10-01

2.  Treatment of Cutaneous Lupus Erythematosus: Review and Assessment of Treatment Benefits Based on Oxford Centre for Evidence-based Medicine Criteria.

Authors:  R R Winkelmann; Grace K Kim; James Q Del Rosso
Journal:  J Clin Aesthet Dermatol       Date:  2013-01

Review 3.  [Terbinafine : Drug-induced lupus erythematodes and triggering of psoriatic skin lesions].

Authors:  P Mayser
Journal:  Hautarzt       Date:  2016-09       Impact factor: 0.751

4.  Terbinafine-induced subacute cutaneous lupus erythematosus in two patients with systemic lupus erythematosus successfully treated with topical corticosteroids.

Authors:  Agnieszka Kalińska-Bienias; Cezary Kowalewski; Katarzyna Woźniak
Journal:  Postepy Dermatol Alergol       Date:  2013-08-27       Impact factor: 1.837

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.